

For further information contact:
Robert B Harris, Ph.D.
President/CEO
Commonwealth Biotechnologies, Inc.
804-648-3820

Commonwealth Biotechnologies, Inc. Teams with Fisher Scientific to Sell its Services and Products

Distribution and Service Agreement Puts Fisher Sales force to Work for CBI

RICHMOND, Va., Sept.7, 2004 — Commonwealth Biotechnologies, Inc. (NASDAQ SmallCap Market: CBTE), a life-sciences contract research organization and biotechnology company, today announced that it has entered into an exclusive distribution and sales agreement with Fisher Scientific LLC, based in Pittsburgh, a world-leading provider of equipment, supplies, and services for the laboratory and global scientific-research markets.

The relationship will focus primarily on providing project-based research services to Fisher customers.

CBI and Fisher formally executed an agreement under which CBI will offer its premier platform technology services through Fisher. In addition, Fisher will distribute CBI products including AccuTrac[®], its patented reagent used in DNA sequencing.

“Execution of the Fisher agreement represents a major step in CBI’s continuing efforts to expand its commercial sector customer base. We could not ask for a better partner in this initiative. CBI will get unparalleled exposure to a very broad range of potential clients,” said Richard J. Freer, Ph.D., Chairman and COO of CBI.

Charles Waldrige, Senior Vice President, Strategic Business Initiatives, CBI, added, “This agreement represents a strategic opportunity for CBI, building our brand and product offerings in the life-science sector.”

Founded in 1992, CBI is located in Gateway Centre, Chesterfield County at 601 Biotech Drive, 23235 (1-800-735-9224). CBI provides comprehensive research and development services to more than 2,800 private, government, and academic customers in the global biotechnology industry. For more information, visit CBI on the Web at www.cbi-biotech.com.

#

No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in CBI’s filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. Specifically, CBI cannot guarantee that the Agreement executed with Fisher Scientific LLC will produce any revenues or prospects referenced herein. CBI undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.